A survival benefit persisted for hypophysitis ( p = 0.03) and hepatitis ( p = 0.04) after adjusting for immortal time bias, whereas rheumatic ( p = 0.05) and skin-related irAE ( p = 0.06) where borderline significant.
← all excerpts
Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab.
1
—
—